Illumina Introduces a New AI algorithm PromoterAI: Stock to Gain?
Illumina Inc. ILMN recently introduced PromoterAI, a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome. PromoterAI turns data into insights to help researchers accelerate new breakthroughs in diagnosis for rare diseases. It is the latest addition to the company's artificial intelligence ("AI") and software portfolio.
Since the announcement on May 29, ILMN's shares declined 0.2%, closing at $84.28 yesterday.
The company is breaking new ground with AI technology. In 2019, the Illumina Artificial Intelligence Lab released SpliceAI, a deep learning tool for interpreting noncoding cryptic splice mutations. In 2023, Illumina released PrimateAI-3D, which predicts the pathogenicity of protein-coding variants based on evolutionary conservation and protein structure. PromoterAI is the latest genomic AI algorithmic innovation from Illumina. As a result, we expect the news to boost market sentiment toward ILMN stock.
Illumina presently has a market capitalization of $13.34 billion. The company's earnings yield of 5.1% sits comfortably against the industry's -31.7%. It delivered a trailing four-quarter average earnings surprise of 56.4%.
Built on state-of-the-art deep learning neural networks, PromoterAI brings unprecedented precision to the interpretation of promoter variants. With PromoterAI applied to whole-genome sequencing ("WGS") data analysis, clinical researchers are empowered to better understand the etiology and drug target potential for rare genetic diseases, common diseases and oncology.
PromoterAI will be accessible through Illumina Connected Software, and it is now available as part of DRAGEN secondary analysis. Precomputed PromoterAI scores for all human promoter single-nucleotide variants are freely available for academic and noncommercial research use.
Currently, only about 30% of rare disease patients receive an accurate diagnosis from exome sequencing. For many patients, insights may be hidden in what are known as "noncoding regions," which comprise over 98% of the genome and may hold the key to increasing the diagnostic rate.
Promoters are key noncoding elements that define where transcription of a gene begins. When promoters are disrupted by genetic mutations, it can have profound consequences for downstream gene expression. The PromoterAI algorithm interprets the genetic sequence of promoters, thus opening the door to precise diagnoses for more patients with rare diseases.
Image Source: Zacks Investment Research
Per Dimension Market Research's report, AI in the genomics market is estimated to be valued at $1.40 billion in 2025. It is further anticipated to reach $44.93 billion by 2034 at a compound annual growth rate of 47%. Key factors driving the market growth are increasing demand for precision medicine, rising R&D expenditure and growing demand for effective handling tools for managing large data.
On Tuesday, Illumina received approval from Japan's Ministry of Health, Labour and Welfare for TruSightTM Oncology (TSO) Comprehensive for Class III/IV Medical Device (Specially Controlled Medical Device). The TSO Comprehensive is the first U.S. FDA-approved, distributable comprehensive genomic profiling in vitro diagnostics (IVD) kit with pan-cancer CDx claims in the United States.
Over the past three months, ILMN's shares have risen 0.1% against the industry's 8.5% decline.
Illumina currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space include Phibro Animal Health PAHC, Hims & Hers Health HIMS and Prestige Consumer Healthcare PBH. While Phibro Animal Health sports a Zacks Rank #1 (Strong Buy) at present, Hims & Hers Health and Prestige Consumer Health carry a Zacks Rank #2 (Buy) each. You can see the complete list of today's Zacks #1 Rank stocks here.
Estimates for Phibro Animal Health's fiscal 2025 earnings per share have jumped 3.6% to $2.01 in the past 30 days. Shares of the company have rallied 37.9% in the past year compared with the industry's 10.1% growth. Its earnings yield of 8.7% compares comfortably with the industry's 0.5%. PAHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 30.6%.
Hims & Hers Health's shares have surged 172.5% in the past year. Estimates for the company's 2025 earnings per share have jumped 12.5% to 72 cents in the past 30 days. HIMS' earnings beat estimates in two of the trailing four quarters, matched in one and missed in the other, the average surprise being 19.6%. In the last reported quarter, it posted an earnings surprise of 66.7%.
Estimates for Prestige Consumer Healthcare's fiscal 2026 earnings per share have increased 1 cent to $4.77 in the past 30 days. Shares of the company have jumped 37.2% in the past year compared with the industry's 10.1% growth. PBH's earnings surpassed estimates in three of the trailing four quarters and matched on one occasion, the average surprise being 2.8%. In the last reported quarter, it delivered an earnings surprise of 1.5%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Illumina, Inc. (ILMN) : Free Stock Analysis Report
Prestige Consumer Healthcare Inc. (PBH) : Free Stock Analysis Report
Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report
Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
3 days ago
- Forbes
Illumina's New CIO Brings R&D Mindset As AI Transforms Genomics
Illumina this month named Mark Field as its next Chief Information Officer, adding a veteran technology and R&D executive to its leadership team as the DNA sequencing giant navigates the next wave of AI and innovation in genomics. Field, who started earlier this month, is based in San Diego and reports to CEO Jacob Thaysen. He succeeds Carissa Rollins, who retired in April. With a three-decade career in enterprise IT and life sciences, Field brings a blend of corporate technology and scientific R&D experience to the role. Illumina CIO Mark Field He began his career at Oracle in 1995, gaining early insight into the internet's disruptive potential. It's a shift he sees mirrored today with the rise of AI and breakthroughs in personalized medicine. 'For the genomic age, it feels just like 1995,' Field said in an interview. Following his time at Oracle, Field led technology at Life Technologies, a life sciences company later acquired by Thermo Fisher Scientific. He was CTO at Thermo Fisher before joining Insulet Corporation, which develops medical devices for people with diabetes and other conditions. Each role reinforced his interest in how digital tools and data can accelerate scientific discovery and directly improve health outcomes, he said. Over the past few weeks, Field has been meeting teams and working to understand the ins and outs of Illumina's operations as he develops a roadmap for the future. 'My goal is to be the best partner and deliver value to the various businesses,' he said. Field says his past experience leading R&D functions in addition to corporate IT makes him well equipped to be a strong partner with that organization at Illumina. R&D is "a completely different way to perceive the world, about getting out in front, having the best product,' he said. While it's a different mindset than the one usually held by IT, technology, data and software are key to progress across both functions. Headquartered in San Diego, Illumina sells genetic sequencing products and services to medical researchers and other customers around the world. Its products are used in applications across life sciences, oncology, reproductive health, agriculture, among other segments. Illumina reported $4.3 billion in revenue for fiscal year 2024. In its most recent earnings report, the company lowered its full-year guidance and announced a $100 million cost reduction program amid ongoing geopolitical and tariff-related impacts, including a ban on imports of Illumina's products in China. Even as the company grapples with near-term headwinds, Field remains optimistic about its long-term trajectory as innovation in science and technology continues to accelerate. 'I'm more thrilled today than I was yesterday, and more thrilled yesterday than I was when I started,' he said. 'I knew it was a great company, but its potential is what's truly exciting me now.'
Yahoo
4 days ago
- Yahoo
3 Top Genomics Stocks to Add to Your Portfolio in 2025
An updated edition of the March 28, 2025, article. The rapid evolution of genomics, the study of genes and their functions, in recent times has paved the way for a revolutionary era in genetic medicine. Given the constant need for innovative medical treatments, genomics holds the key to the future of the medical world. In simpler terms, genomics includes the study of a complete set of genes, their work process and way of interacting with each other and the environment. The primary focus is to evaluate all the genes of an organism rather than individual genes. Of late, there have been several breakthroughs in this field, attracting the attention of pharma and biotech companies. Genetic information is being used to evaluate individual responses to drugs, leading to the development of targeted therapies. Interestingly, genomics has ushered in innovative concepts, such as synthetic biology, which applies engineering principles to biology. Synthetic biology products serve life sciences researchers across a variety of healthcare applications, including drug discovery, disease detection, enzyme engineering, gene editing and basic academic research. The recent spotlight on companies in the evolving genomics sector can be attributed to a drastic reduction in the cost, accuracy, and time required to map an individual's entire genome. A major player in this field is Illumina ILMN, a global leader in sequencing and array-based solutions for genetic and genomic analysis. While some companies are utilizing genetic sequencing to develop solutions not only for healthcare but also for other areas, diagnostic companies leverage sequencing data to identify specific genetic variations and map them to a known condition. Another breakthrough is the development of genome editing approaches, such as CRISPR/Cas9 technology. Gene editing companies, such as BEAM Therapeutics BEAM and CRISPR Therapeutics AG CRSP, hold potential to treat and cure diseases caused by genetic variants. As the name suggests, they make changes or correct defects in the organism's DNA. Per estimates, the genomics market will reach $157.47 billion by 2033. Per Grandview research, the global synthetic biology market size was valued at $16.22 billion in 2024 and is projected to witness a CAGR of 17.30% from 2025 to 2030. If you're looking to capitalize on this trend, our Genomics and Synthetic Biology screen makes it easy to identify high-potential stocks at any given time. At present, investors can consider adding stocks like Intellia Therapeutics NTLA, uniQure QURE and Verve Therapeutics VERV to their portfolio. Explore 30 cutting-edge investment themes with Zacks Thematic Screens and uncover your next big opportunity. Intellia Therapeutics is a clinical-stage gene editing company, focused on developing drugs with CRISPR-based therapies. NTLA is leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. The in vivo programs use CRISPR to enable precise editing of disease-causing genes directly inside the human body. NTLA's lead in vivo product candidates are nex-z for the treatment of ATTR amyloidosis and NTLA-2002 for the treatment of HAE. NTLA-2002 is a wholly owned, investigational in vivo CRISPR-based therapy designed to knock out the kallikrein B1 gene in the liver, with the goal of achieving lifelong control of HAE attacks after a single dose. Nex-z is an investigational CRISPR-based therapy designed to inactivate the TTR gene in liver cells, thereby preventing the production of TTR protein for the treatment of ATTR amyloidosis. Both are currently in phase III studies. NTLA has collaborated with Regeneron for Nex-z. This Zacks Rank #2 (Buy) company is also advancing ex vivo applications to address immuno-oncology and autoimmune diseases, where CRISPR is used as the tool to create the engineered cell therapy outside the body. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. uniQure is advancing a focused pipeline of innovative gene therapies for the treatment of Huntington's disease, amyotrophic lateral sclerosis caused by mutations in superoxide dismutase 1 ('SOD1-ALS'), refractory mesial temporal lobe epilepsy ('mTLE') and Fabry disease. The company has made good pipeline progress. The FDA recently granted Breakthrough Therapy designation to AMT-130 for the treatment of Huntington's disease. In March 2025, QURE held a Type B meeting with the FDA to discuss chemistry, manufacturing and controls requirements for AMT-130, in support of a planned biologics license application ('BLA') submission. An additional Type B meeting (focused on the pivotal statistical analysis plan) was also held. The company is also conducting a phase I/IIa study (GenTLE) on AMT-260 for the treatment of MTLE in the United States. A phase I/IIa study on AMT-191 for the treatment of Fabry disease is also ongoing. AMT-162 is being evaluated for the treatment of SOD1-ALS in a phase I/II study. The successful development of any of these candidates will be a significant boost for this Zacks Rank #2 company. Verve Therapeutics is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease (CVD). The primary objective is to transition CVD treatment from chronic therapies to single-course, gene-editing medicines. VERV is developing a pipeline of gene editing programs targeting the three lipoprotein pathways — low-density lipoprotein, or LDL, triglyceride-rich lipoproteins, and lipoprotein(a), or Lp(a) — that drive atherosclerotic cardiovascular disease (ASCVD), the most common form of CVD. VERV's lead clinical-stage programs target the PCSK9 and ANGPTL3 genes, which have been extensively validated as targets for lowering LDL cholesterol, or LDL-C. VERVE-102 targets PCSK9 and is designed to permanently turn off the PCSK9 gene in the liver. The candidate is being evaluated in the open-label phase Ib Heart-2 study. The study is designed to evaluate the safety and tolerability of VERVE-102 in adult patients with heterozygous familial hypercholesterolemia, or HeFH, and/or premature coronary artery disease. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver. VERVE-201 is being evaluated in the open-label phase Ib study designed to evaluate the safety and tolerability in adult patients with refractory hypercholesterolemia. VERVE-301 is being developed in collaboration with Lilly. The company also carries a Zacks Rank #2. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Illumina, Inc. (ILMN) : Free Stock Analysis Report Beam Therapeutics Inc. (BEAM) : Free Stock Analysis Report uniQure N.V. (QURE) : Free Stock Analysis Report Intellia Therapeutics, Inc. (NTLA) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report Verve Therapeutics, Inc. (VERV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Yahoo
Epigenetics Diagnostics Market Analysis 2025-2034: Oncology Led with 68.7% Share in 2024, Driven by Demand for Early and Precise Cancer Detection Through Epigenetic Markers
The market, dominated by DNA methylation, sees significant contributions from North America, with the U.S. leading. Major players include Thermo Fisher Scientific, Illumina, and Roche Diagnostics, focusing on innovative tools that enhance precision medicine. Epigenetics Diagnostics Market Dublin, June 17, 2025 (GLOBE NEWSWIRE) -- The "Epigenetics Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to Global Epigenetics Diagnostics Market was valued at USD 15.5 billion in 2024 and is estimated to grow at a CAGR of 16.5% to reach USD 70.7 billion by 2034. The market is gaining momentum due to the rising awareness of how epigenetic mechanisms contribute to disease development, especially in complex and chronic conditions. The continuous evolution of diagnostic technologies is another key factor driving growth. Increasing cases of chronic illnesses and cancer globally have created a pressing demand for early and accurate detection methods. This, in turn, has fueled the need for advanced epigenetic biomarkers and testing assays. Additionally, the expanding use of next-generation sequencing technologies and AI-powered analytics has significantly improved the efficiency and scalability of epigenetic diagnostics. The growing preference for non-invasive procedures like liquid biopsies has further encouraged market adoption. Collaborations among pharmaceutical manufacturers, research bodies, and diagnostics firms are increasing to develop safer and more effective diagnostic tools. These initiatives are helping accelerate the transition of epigenetic diagnostics from research labs to mainstream clinical use. With heightened interest in precision medicine, the industry is seeing a sharp focus on the development of highly accurate and scalable solutions that support early intervention and personalized treatment market centers on technologies used to detect and analyze epigenetic markers, including DNA methylation and histone modifications, which are pivotal in identifying disease risks and progression. These diagnostics offer valuable insights for early-stage diagnosis and treatment planning across a range of conditions, including cancer and neurological disorders. Based on product type, the market is segmented into instruments, kits and reagents, and software and services. In 2024, the kits and reagents category led the market with a valuation of USD 7.6 billion. These products are integral to routine diagnostic workflows and are extensively used in clinical settings, academic research, and pharmaceutical development. Their ease of use, reliability, and compatibility with automated and high-throughput systems such as PCR and sequencing platforms make them widely preferred. Continuous improvements in assay sensitivity and integration with advanced technologies are driving further adoption. Additionally, the increasing emphasis on environmentally sustainable and cost-effective reagent development has enhanced accessibility, particularly in developing terms of application, the epigenetics diagnostics market is split between oncology and non-oncology diagnostics. The oncology diagnostics segment commanded a dominant share of 68.7% in 2024. This growth is propelled by the demand for early and precise cancer detection using epigenetic markers. DNA methylation and histone changes are commonly linked to various forms of cancer and serve as effective indicators for early diagnosis. The rising number of cancer cases, coupled with the shift toward personalized therapies, has heightened interest in epigenetic diagnostics. Awareness campaigns and initiatives promoting early detection and treatment are also playing a pivotal role in expanding this on technology, the market includes DNA methylation, histone methylation, microRNA modification, chromatin structure analysis, and other methods. DNA methylation dominated the landscape with a value of USD 6.3 billion in 2024 and is projected to reach USD 28.5 billion by 2034. This segment's strength lies in its capacity to identify disease-specific methylation markers, enabling earlier and more accurate diagnoses. Techniques like bisulfite sequencing, methylation-specific PCR, and array-based assays have advanced the precision of methylation studies, allowing for more effective disease monitoring. Integration of these methods with next-generation sequencing tools continues to improve test sensitivity and throughput, making them increasingly valuable in both research and clinical end user, the market is divided into hospitals and clinics, pharmaceutical and biotechnology companies, diagnostic laboratories, and others. Hospitals and clinics led the market in 2024 and are expected to reach USD 25.9 billion by 2034. These institutions play a vital role in deploying epigenetic testing for diagnostics, prognosis, and treatment monitoring. Their infrastructure and expertise allow for comprehensive testing and interpretation, including genetic counseling and interdisciplinary collaboration. The trend toward precision medicine has further boosted demand within hospitals, which often serve as central hubs for patient care and advanced North America held the largest share in 2024, accounting for 39.7% of the global market. The U.S. alone was valued at USD 5.4 billion in the same year. Factors contributing to the region's dominance include robust healthcare infrastructure, high investments in genomic research, and increased adoption of precision diagnostics. Government initiatives and funding support, especially from research bodies, have helped accelerate innovation in epigenetics. The growing burden of chronic diseases and a strong emphasis on non-invasive diagnostics continue to propel demand in the companies - Thermo Fisher Scientific, Illumina, QIAGEN, Agilent Technologies, and Roche Diagnostics - collectively held around 65% of the market share. These firms stay ahead through continuous innovations in sequencing systems, methylation detection tools, and integrated bioinformatics. Their expanding portfolios, including single-cell analysis and targeted panels, align with the rising demand for tailored diagnostic Market Analysis and Forecast Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape Competitive landscape with Porter's Five Forces and PESTEL analysis Market size, segmentation, and regional forecasts In-depth company profiles, business strategies, financial insights, and SWOT analysis Key Attributes Report Attribute Details No. of Pages 133 Forecast Period 2024-2034 Estimated Market Value (USD) in 2024 $15.5 Billion Forecasted Market Value (USD) by 2034 $70.7 Billion Compound Annual Growth Rate 16.5% Regions Covered Global Key Topics CoveredChapter 1 Methodology and Scope1.1 Market scope and definitions1.2 Research design1.2.1 Research approach1.2.2 Data collection methods1.3 Base estimates and calculations1.3.1 Base year calculation1.3.2 Key trends for market estimation1.4 Forecast model1.5 Primary research and validation1.5.1 Primary sources1.5.2 Data mining sourcesChapter 2 Executive Summary2.1 Industry 360 degree synopsisChapter 3 Industry Insights3.1 Industry ecosystem analysis3.2 Industry impact forces3.2.1 Growth drivers3.2.1.1 Increasing prevalence of cancer and chronic diseases3.2.1.2 Advancements in epigenomics research and technology3.2.1.3 Growing demand for non-invasive diagnostics3.2.2 Industry pitfalls and challenges3.2.2.1 High cost of epigenetic diagnostics technologies3.2.2.2 Limited standardization of testing methods3.3 Growth potential analysis3.4 Regulatory landscape3.5 Trump administration tariffs3.5.1 Impact on trade3.5.1.1 Trade volume disruptions3.5.1.2 Retaliatory measures3.5.2 Impact on the Industry3.5.2.1 Supply-side impact (raw materials)3.5.2.1.1 Price volatility in key materials3.5.2.1.2 Supply chain restructuring3.5.2.1.3 Production cost implications3.5.2.2 Demand-side impact (selling price)3.5.2.2.1 Price transmission to end markets3.5.2.2.2 Market share dynamics3.5.2.2.3 Consumer response patterns3.5.3 Key companies impacted3.5.4 Strategic industry responses3.5.4.1 Supply chain reconfiguration3.5.4.2 Pricing and product strategies3.5.4.3 Policy engagement3.5.5 Outlook and future considerations3.6 Technological landscape3.7 Future market trends3.8 Porter's analysis3.9 PESTEL analysisChapter 4 Competitive Landscape, 20244.1 Introduction4.2 Company market share analysis4.3 Company matrix analysis4.4 Competitive analysis of major market players4.5 Competitive positioning matrix4.6 Strategy dashboardChapter 5 Market Estimates and Forecast, by Product, 2021-2034 ($ Mn)5.1 Key trends5.2 Kits and reagents5.3 Instruments5.4 Software and servicesChapter 6 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)6.1 Key trends6.2 Oncology diagnostics6.3 Non-oncology diagnosticsChapter 7 Market Estimates and Forecast, by Technology, 2021-2034 ($ Mn)7.1 Key trends7.2 DNA methylation7.3 Histone methylation7.4 MicroRNA modification7.5 Chromatin structures7.6 Other technologiesChapter 8 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)8.1 Key trends8.2 Hospital and clinics8.3 Pharmaceutical and biotechnology companies8.4 Diagnostic laboratories8.5 Other end useChapter 9 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)9.1 Key trends9.2 North America9.2.1 U.S.9.2.2 Canada9.3 Europe9.3.1 Germany9.3.2 UK9.3.3 France9.3.4 Spain9.3.5 Italy9.3.6 Netherlands9.4 Asia-Pacific9.4.1 China9.4.2 Japan9.4.3 India9.4.4 Australia9.4.5 South Korea9.5 Latin America9.5.1 Brazil9.5.2 Mexico9.5.3 Argentina9.6 Middle East and Africa9.6.1 South Africa9.6.2 Saudi Arabia9.6.3 UAEChapter 10 Company Profiles10.1 Abcam10.2 Agilent Technologies10.3 Diagenode10.4 Dovetail Genomics10.5 Element Biosciences10.6 Illumina10.7 Merck10.8 New England Biolabs10.9 PacBio10.10 Promega10.11 QIAGEN10.12 Roche Diagnostics10.13 Thermo Fisher Scientific10.14 Zymo Research For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Epigenetics Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
